VectivBio Announces Completion of Enrollment for Colon-in-Continuity (CIC) Cohort of STARS Pivotal Phase III Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

VectivBio Holding AG announced the completion of enrollment of the Colon-in-Continuity cohort for the company’s Phase III STARS (STudy of ApRglutide in SBS) pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure.